Diabetic Nephropathy Clinical Trial
Official title:
Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)
The purpose of this study is to compare the progression of kidney disease in subjects with Diabetes mellitus type 2 and Advanced Diabetic Nephropathy treated by routine follow-up as a general care and in subjects treated by multi-factorial intervention in the Diabetes-Renal Clinic.
In this study, the overall objective is comparison of progression of renal insufficiency in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4) randomized into multifactorial intervention in the Diabetes-Renal Clinic (study group) and into usual care (control group). The multifactorial intervention includes the following: 1. Blood pressure control to the goal of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using a protocol that includes therapy with ACE inhibitors, ARBs or their combination. 2. Tight glucose control using SMBG and Lantus/Apidra self-escalation regimen. 3. Use of hypolipidemic therapy to achieve targets of LDL of < 70 mg/dl, HDL > 40/50 mg/dl (males/females) [since you said that HDL is not a target because there are no meds for it I deleted HDL;] and triglycerides of less than 200 mg/dl. 4. Patient enhanced self-management provided by combined diabetes-renal education curriculum (taught by certified diabetes and renal educators). 5. Behavior and social intervention (motivational interviews and social assessment) provided as needed by social workers. 6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors. 7. Weight loss with lifestyle and diet modification. Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04562025 -
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
|
N/A | |
Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
Recruiting |
NCT02501772 -
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy
|
N/A | |
Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 |